Knight Therapeutics (GUD) Insider Trading & Ownership C$5.19 -0.03 (-0.57%) (As of 11/15/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Knight Therapeutics (TSE:GUD) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage45.62%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)C$2.47 MNumber OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)C$3.18 M Get GUD Insider Trade Alerts Want to know when executives and insiders are buying or selling Knight Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address GUD Insider Buying and Selling by Quarter Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Knight Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/12/2024Sime ArmoyanInsiderBuy90,300C$5.13C$463,672.4411/11/2024Samira SakhiaDirectorBuy20,000C$5.15C$103,000.009/16/2024Sime ArmoyanInsiderSell300,000C$6.13C$1,839,000.008/19/2024Amal KhouriSenior OfficerSell5,000C$5.78C$28,919.008/15/2024Amal KhouriSenior OfficerSell500C$5.75C$2,875.008/13/2024Amal KhouriSenior OfficerSell5,000C$5.75C$28,750.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 7/11/2024Amal KhouriSenior OfficerSell10,000C$5.70C$57,000.007/3/2024Amal KhouriSenior OfficerSell10,000C$5.72C$57,200.006/10/2024Amal KhouriSenior OfficerSell20,000C$5.80C$116,022.006/5/2024Jonathan Ross GoodmanDirectorBuy5,000C$5.80C$29,000.005/29/2024Robert Nathaniel LandeDirectorSell15,000C$5.91C$88,600.505/23/2024Robert Nathaniel LandeDirectorSell20,000C$5.94C$118,710.005/7/2024Sime ArmoyanInsiderSell15,000C$5.95C$89,250.004/11/2024Sime ArmoyanInsiderSell10,900C$5.95C$64,855.004/1/2024Sime ArmoyanInsiderBuy6,200C$5.25C$32,550.003/25/2024Sime ArmoyanInsiderBuy351,000C$5.25C$1,842,750.001/22/2024Sime ArmoyanInsiderSell28,200C$5.75C$162,150.001/19/2024Sime ArmoyanInsiderSell91,000C$5.75C$523,250.00 (Data available from 1/1/2013 forward) GUD Insider Trading Activity - Frequently Asked Questions Who is on Knight Therapeutics's Insider Roster? The list of insiders at Knight Therapeutics includes Amal Khouri, Janice Jean Murray, Jonathan Ross Goodman, Long Zone Holdings Inc. , Robert Nathaniel Lande, Samira Sakhia, and Sime Armoyan. Learn more on insiders at GUD. What percentage of Knight Therapeutics stock is owned by insiders? 45.62% of Knight Therapeutics stock is owned by insiders. Learn more on GUD's insider holdings. Which Knight Therapeutics insiders have been buying company stock? The following insiders have purchased GUD shares in the last 24 months: Jonathan Ross Goodman (C$29,000.00), Samira Sakhia (C$103,000.00), and Sime Armoyan (C$2,459,495.04). How much insider buying is happening at Knight Therapeutics? Insiders have purchased a total of 500,000 GUD shares in the last 24 months for a total of C$2,591,495.04 bought. Which Knight Therapeutics insiders have been selling company stock? The following insiders have sold GUD shares in the last 24 months: Amal Khouri (C$290,766.00), Robert Nathaniel Lande (C$207,310.50), and Sime Armoyan (C$2,678,505.00). How much insider selling is happening at Knight Therapeutics? Insiders have sold a total of 530,600 Knight Therapeutics shares in the last 24 months for a total of C$3,176,581.50 sold. Knight Therapeutics Key ExecutivesMr. Jonathan Ross Goodman B.A. (Age 55)L.L.B., M.B.A., Executive Chairman Compensation: $250.94k1 recent tradesMs. Samira Sakhia BCom (Age 56)CA, CPA, MBA, President, CEO & Director Compensation: $674.28kMr. Arvind UtchanahChief Financial OfficerMs. Amal Khouri B.Sc.M.B.A., Chief Business OfficerMr. Jeff MartensGlobal Vice President of CommercialMr. Stephani SaverioVice President of Business DevelopmentMr. Leopoldo BosanoVice-President of Manufacturing & OperationsMs. Monica PercarioGlobal Vice President of Scientific AffairsMr. Henrique DiasGlobal Director of MarketingMs. Susan Caroline EmblemGlobal Vice President of Human Resources More Insider Trading Tools from MarketBeat Related Companies WEED Insider Trades ACB Insider Trades OGI Insider Trades RX Insider Trades HLS Insider Trades SUGR Insider Trades MDP Insider Trades DB Insider Trades WLLW Insider Trades NDVA Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (TSE:GUD) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
